

# Derya Tilki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/972956/publications.pdf>

Version: 2024-02-01

183  
papers

5,920  
citations

101543

36  
h-index

95266

68  
g-index

184  
all docs

184  
docs citations

184  
times ranked

5140  
citing authors

#	ARTICLE	IF	CITATIONS
1	MRI as a screening tool for prostate cancer: current evidence and future challenges. <i>World Journal of Urology</i> , 2023, 41, 921-928.	2.2	5
2	Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aN0M0 Renal Cell Carcinoma Patients. <i>European Urology Focus</i> , 2022, 8, 191-199.	3.1	8
3	Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 399-408.	3.1	29
4	Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy. <i>European Urology Focus</i> , 2022, 8, 710-717.	3.1	12
5	Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 139-148.	3.9	28
6	Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2022, 8, 690-700.	3.1	10
7	Feasibility and outcome of radical prostatectomy following inductive neoadjuvant therapy in patients with suspicion of rectal infiltration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 59.e7-59.e12.	1.6	5
8	External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. <i>International Journal of Urology</i> , 2022, 29, 17-24.	1.0	7
9	Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. <i>Cancer Causes and Control</i> , 2022, 33, 25-35.	1.8	4
10	CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo. <i>Cancer Gene Therapy</i> , 2022, 29, 49-61.	4.6	3
11	Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. <i>Prostate</i> , 2022, 82, 78-85.	2.3	3
12	Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. <i>International Journal of Urology</i> , 2022, 29, 96-96.	1.0	3
13	Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer. <i>Prostate</i> , 2022, 82, 254-259.	2.3	3
14	Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis. <i>Cancers</i> , 2022, 14, 740.	3.7	5
15	Biomarkers to personalize treatment with <sup>177</sup> Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210819.	3.2	12
16	Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups. <i>Prostate</i> , 2022, 82, 676-686.	2.3	4
17	Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy. <i>Cancers</i> , 2022, 14, 1222.	3.7	7
18	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 6-11.	1.9	4

#	ARTICLE	IF	CITATIONS
19	Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients. <i>Prostate</i> , 2022, 82, 687-694.	2.3	3
20	Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death. <i>Journal of Clinical Oncology</i> , 2022, 40, 2186-2192.	1.6	14
21	Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan-confined prostate cancer. <i>Prostate</i> , 2022, 82, 949-956.	2.3	3
22	Radiation therapy after radical prostatectomy is associated with higher other-cause mortality. <i>Cancer Causes and Control</i> , 2022, 33, 769-777.	1.8	1
23	Urethral Sphincter Length but Not Prostatic Apex Shape in Preoperative MRI Is Associated with Mid-Term Continence Rates after Radical Prostatectomy. <i>Diagnostics</i> , 2022, 12, 701.	2.6	3
24	Oncologic outcomes of organ-confined Gleason grade group 4-5 prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 161.e9-161.e14.	1.6	3
25	Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. <i>European Urology</i> , 2022, 81, 337-346.	1.9	33
26	Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates. <i>Prostate</i> , 2022, , .	2.3	4
27	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer—Current State and Future Perspectives. <i>Cancers</i> , 2022, 14, 147.	3.7	2
28	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	1.9	51
29	Full functional-length urethral sphincter- and neurovascular bundle preservation improves long-term continence rates after robotic-assisted radical prostatectomy. <i>Journal of Robotic Surgery</i> , 2022, , 1.	1.8	2
30	Contemporary Pathological Stage Distribution After Radical Prostatectomy in North American High-Risk Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e380-e389.	1.9	5
31	Metastatic stage vs complications at radical nephrectomy with inferior vena cava thrombectomy. <i>Surgical Oncology</i> , 2022, 42, 101783.	1.6	2
32	Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level. <i>Prostate</i> , 2022, 82, 1210-1218.	2.3	2
33	Outcomes of robotic-assisted versus open radical cystectomy in a large-scale, contemporary cohort of bladder cancer patients. <i>Journal of Surgical Oncology</i> , 2022, 126, 830-837.	1.7	7
34	Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	1.6	1
35	Regression Discontinuity Analysis of Salvage Radiotherapy in Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 817-820.	5.4	1
36	Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2021, 7, 742-751.	3.1	19

#	ARTICLE	IF	CITATIONS
37	Implementation of Intraoperative Frozen Section During Radical Prostatectomy: Short-term Results from a German Tertiary-care Center. <i>European Urology Focus</i> , 2021, 7, 95-101.	3.1	37
38	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancerâ€™2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2021, 79, 243-262.	1.9	1,545
39	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part IIâ€™2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	1.9	633
40	Oncological outcomes of pathologically organ-confined, lymph node-positive prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 234.e1-234.e7.	1.6	3
41	Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 193-201.	3.9	7
42	External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 253-260.	3.9	6
43	Effect of prostatic apex shape (Lee types) and urethral sphincter length in preoperative MRI on very early continence rates after radical prostatectomy. <i>International Urology and Nephrology</i> , 2021, 53, 1297-1303.	1.4	12
44	Incidence rates and contemporary trends in primary urethral cancer. <i>Cancer Causes and Control</i> , 2021, 32, 627-634.	1.8	15
45	<sup>68</sup> Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy. <i>European Urology Focus</i> , 2021, 7, 288-293.	3.1	16
46	Nonâ€cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy. <i>Prostate</i> , 2021, 81, 728-735.	2.3	11
47	Radical Prostatectomy: Sequelae in the Course of Time. <i>Frontiers in Surgery</i> , 2021, 8, 684088.	1.4	4
48	Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. <i>World Journal of Urology</i> , 2021, 39, 3781-3787.	2.2	9
49	Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 296.e21-296.e29.	1.6	24
50	Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American populationâ€based study. <i>International Journal of Urology</i> , 2021, 28, 834-839.	1.0	5
51	Correlation of MRI-Lesion Targeted Biopsy vs. Systematic Biopsy Gleason Score with Final Pathological Gleason Score after Radical Prostatectomy. <i>Diagnostics</i> , 2021, 11, 882.	2.6	13
52	Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1172-1178.	1.0	7
53	Presence of biopsy Gleason pattern 5â€%+â€%3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns+. <i>Prostate</i> , 2021, 81, 778-784.	2.3	2
54	Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. <i>International Journal of Urology</i> , 2021, 28, 862-869.	1.0	22

#	ARTICLE	IF	CITATIONS
55	Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 830.e17-830.e26.	1.6	17
56	Immunohistochemistry for Prostate Biopsyâ€”Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making. <i>Current Oncology</i> , 2021, 28, 2123-2133.	2.2	10
57	Twentyâ€”year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort. <i>Prostate</i> , 2021, 81, 849-856.	2.3	14
58	Early prostate cancer recurrence with prostateâ€”specific membrane antigen positron emission tomography positive unilateral pelvic lesion(s): is oneâ€”sided salvage extended lymph node dissection enough? (ProStone, NCT04271579). <i>BJU International</i> , 2021, 128, 301-303.	2.5	4
59	Prostateâ€”specific antigen levels of $\geq 4$ and $> 4$ ng/mL and risk of prostate cancerâ€”specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer. <i>Cancer</i> , 2021, 127, 2222-2228.	4.1	6
60	Increasing rates of NCCN high and very highâ€”risk prostate cancer versus number of prostate biopsy cores. <i>Prostate</i> , 2021, 81, 874-881.	2.3	15
61	Assessment of the optimal number of positive biopsy cores to discriminate between cancerâ€”specific mortality in highâ€”risk versus very highâ€”risk prostate cancer patients. <i>Prostate</i> , 2021, 81, 1055-1063.	2.3	2
62	Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy. <i>Frontiers in Oncology</i> , 2021, 11, 656444.	2.8	2
63	Reply to Benefitâ€”harm ratio of the diagnostic workup in patients with prostate cancer of Gleason score from 9 to 10. <i>Cancer</i> , 2021, 127, 4312-4312.	4.1	0
64	Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. <i>Journal of Clinical Oncology</i> , 2021, 39, 2284-2293.	1.6	54
65	Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer. <i>Journal of Urology</i> , 2021, 206, 69-79.	0.4	12
66	Salvage therapy for prostate cancer after radical prostatectomy. <i>Nature Reviews Urology</i> , 2021, 18, 643-668.	3.8	26
67	The effect of primary urological cancers on survival in men with secondary prostate cancer. <i>Prostate</i> , 2021, 81, 1149-1158.	2.3	5
68	Improvement in overall and cancerâ€”specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. <i>Prostate</i> , 2021, 81, 1374-1381.	2.3	8
69	Increased risk of postoperative inâ€”hospital complications after radical prostatectomy in patients with prior organ transplant. <i>Prostate</i> , 2021, 81, 1294-1302.	2.3	0
70	Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort. <i>European Urology</i> , 2021, 80, 400-404.	1.9	4
71	Circulating Vitamin D and Selenium Levels and Outcome in Prostate Cancer Patients: Lessons from the MARTINI-Lifestyle Cohort. <i>European Urology Focus</i> , 2021, 7, 973-979.	3.1	5
72	The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 754996.	2.8	0

#	ARTICLE	IF	CITATIONS
73	Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 778858.	2.8	7
74	Correlation of Urine Loss after Catheter Removal and Early Continence in Men Undergoing Radical Prostatectomy. <i>Current Oncology</i> , 2021, 28, 4738-4747.	2.2	10
75	Anatomical Fundamentals and Current Surgical Knowledge of Prostate Anatomy Related to Functional and Oncological Outcomes for Robotic-Assisted Radical Prostatectomy. <i>Frontiers in Surgery</i> , 2021, 8, 825183.	1.4	14
76	Poor Adherence to International Cancer Prevention Recommendations Among Patients With Prostate Cancer: First Results From the MARTINI-Lifestyle Cohort. <i>European Urology Focus</i> , 2020, 6, 935-940.	3.1	7
77	Accuracy of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography for the Detection of Lymph Node Metastases Before Salvage Lymphadenectomy. <i>European Urology Focus</i> , 2020, 6, 71-73.	3.1	23
78	The Impact of Anxiety and Depression on Surgical and Functional Outcomes in Patients Who Underwent Radical Prostatectomy. <i>European Urology Focus</i> , 2020, 6, 1199-1204.	3.1	25
79	External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients. <i>International Urology and Nephrology</i> , 2020, 52, 59-66.	1.4	4
80	Effect of bladder neck sparing at robot-assisted laparoscopic prostatectomy on postoperative continence rates and biochemical recurrence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 1.e11-1.e16.	1.6	3
81	Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H. <i>World Journal of Urology</i> , 2020, 38, 1459-1464.	2.2	32
82	Comparison of intra- and postoperative analgesia and pain perception in robot-assisted vs. open radical prostatectomy. <i>World Journal of Urology</i> , 2020, 38, 1451-1457.	2.2	14
83	Timing of radiotherapy after radical prostatectomy. <i>Lancet, The</i> , 2020, 396, 1374-1375.	13.7	17
84	Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair. <i>Cancers</i> , 2020, 12, 2467.	3.7	11
85	Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. <i>European Urology Oncology</i> , 2020, 3, 565-581.	5.4	46
86	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>European Urology</i> , 2020, 78, 661-669.	1.9	74
87	The Significance of Primary Biopsy Gleason 5 in Patients with Grade Group 5 Prostate Cancer. <i>European Urology Focus</i> , 2020, 6, 255-258.	3.1	9
88	Localized Prostate Cancer: Exploring the Boundaries of Current Treatment Paradigms. <i>European Urology Focus</i> , 2020, 6, 199-200.	3.1	0
89	Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 184-190.	1.6	13
90	The impact of very high initial PSA on oncological outcomes after radical prostatectomy for clinically localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 379-385.	1.6	8

#	ARTICLE	IF	CITATIONS
91	Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages " Does extent of tumor involvement matter?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 637.e1-637.e7.	1.6	1
92	Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. <i>Journal of Urology</i> , 2020, 203, 338-343.	0.4	53
93	The Impact of Race and Age on Distribution of Metastases in Patients with Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 962-968.	0.4	11
94	Validation of the Social Security Administration Life Tables (2004"2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. <i>European Urology Focus</i> , 2019, 5, 807-814.	3.1	22
95	A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 395-401.	1.9	9
96	Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e939-e945.	1.9	9
97	Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organ-confined prostate cancer. <i>Prostate</i> , 2019, 79, 1832-1836.	2.3	38
98	Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1153-e1162.	1.9	8
99	The effect of age and comorbidities on early postoperative complications after radical cystectomy: A contemporary population-based analysis. <i>Journal of Geriatric Oncology</i> , 2019, 10, 623-631.	1.0	14
100	Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 575.e1-575.e7.	1.6	4
101	Impact of the estimated blood loss during radical prostatectomy on functional outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 298.e11-298.e17.	1.6	7
102	External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. <i>European Urology</i> , 2019, 75, 896-900.	1.9	74
103	A comparative study of robot-assisted and open radical prostatectomy in 10790 men treated by highly trained surgeons for both procedures. <i>BJU International</i> , 2019, 123, 1031-1040.	2.5	76
104	Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment. <i>World Journal of Urology</i> , 2019, 37, 2657-2662.	2.2	6
105	Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1253-1259.	1.0	6
106	Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. <i>European Urology</i> , 2019, 76, 106-114.	1.9	77
107	Antimicrobial Lubricant Did Not Reduce Infection Rate in Transrectal Biopsy Patients in a Large Randomized Trial Due to Low Complication Rates. <i>European Urology Focus</i> , 2019, 5, 992-997.	3.1	4
108	Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality. <i>JAMA Oncology</i> , 2019, 5, 213.	7.1	62

#	ARTICLE	IF	CITATIONS
109	More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 105-113.e2.	1.9	15
110	Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e130-e139.	1.9	23
111	Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States. <i>World Journal of Urology</i> , 2019, 37, 1305-1313.	2.2	13
112	Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis?. <i>Cancer Epidemiology</i> , 2019, 58, 83-88.	1.9	15
113	Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. <i>European Urology Focus</i> , 2019, 5, 171-178.	3.1	50
114	A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. <i>European Urology Focus</i> , 2019, 5, 449-456.	3.1	11
115	Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery. <i>European Urology Focus</i> , 2019, 5, 50-53.	3.1	52
116	Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches. <i>Journal of Urology</i> , 2019, 202, 725-731.	0.4	62
117	Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care Therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1344-1352.	4.9	8
118	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. <i>Prostate</i> , 2018, 78, 469-475.	2.3	40
119	Is 68 Ga-Prostate-specific Membrane Antigen- <sup>68</sup> ligand Positron Emission Tomography/Computed Tomography Ready To Simplify the Conundrum of Biochemically Recurrent Prostate Cancer?. <i>European Urology</i> , 2018, 73, 662-663.	1.9	1
120	Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients. <i>World Journal of Urology</i> , 2018, 36, 1067-1072.	2.2	18
121	Reply to the letter to the editor: RE: Preisser F, et al. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. <i>The Prostate</i> . 2018;1-7. <i>Prostate</i> , 2018, 78, 692-692.	2.3	2
122	Survival benefit of local versus no local treatment for metastatic prostate cancer- Impact of baseline PSA and metastatic substages. <i>Prostate</i> , 2018, 78, 753-757.	2.3	27
123	Local treatment for metastatic prostate cancer: A systematic review. <i>International Journal of Urology</i> , 2018, 25, 390-403.	1.0	37
124	Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence. <i>Prostate</i> , 2018, 78, 676-681.	2.3	23
125	Antimicrobial lubricant reduces rectal bacteria at transrectal prostate biopsy: results from a prospective randomized trial. <i>World Journal of Urology</i> , 2018, 36, 871-876.	2.2	5
126	Prostate cancer rates in patients with initially negative elastography-targeted biopsy vs. systematic biopsy. <i>World Journal of Urology</i> , 2018, 36, 623-628.	2.2	5



#	ARTICLE	IF	CITATIONS
127	Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. World Journal of Urology, 2018, 36, 1399-1407.	2.2	16
128	Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. European Urology, 2018, 73, 674-683.	1.9	40
129	The Decipher Genomic Classifier Independently Improves Prognostication for Patients After Prostatectomy. European Urology, 2018, 73, 176-177.	1.9	3
130	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. World Journal of Urology, 2018, 36, 7-13.	2.2	23
131	North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients. British Journal of Cancer, 2018, 119, 1552-1556.	6.4	10
132	Radical prostatectomy after previous TUR-P: Oncological, surgical, and functional outcomes. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 527.e21-527.e28.	1.6	16
133	Multiparametric MRI: an important tool to improve risk stratification for active surveillance in prostate cancer. BJU International, 2018, 122, 721-722.	2.5	1
134	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. Cancer Epidemiology, 2018, 56, 118-125.	1.9	19
135	How can we expand active surveillance criteria in patients with low and intermediate risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. BJU International, 2018, 122, 823-830.	2.5	27
136	Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. European Urology Oncology, 2018, 1, 314-320.	5.4	19
137	Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. European Urology, 2018, 74, 693-696.	1.9	19
138	Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer. European Urology Oncology, 2018, 1, 160-168.	5.4	15
139	Getting the Balance Right—The Benefits and Uncertainties of Focal Therapy for Significant Prostate Cancer. European Urology, 2018, 74, 430-431.	1.9	1
140	Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systems. BJU International, 2018, 122, 801-807.	2.5	52
141	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. European Urology, 2018, 74, 376-386.	1.9	58
142	Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins. World Journal of Urology, 2017, 35, 199-206.	2.2	19
143	Association between Lymph Node Counts and Oncological Outcomes in Lymph Node Positive Prostate Cancer. European Urology Focus, 2017, 3, 248-255.	3.1	30
144	Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline. Journal of Urology, 2017, 198, 354-361.	0.4	36

#	ARTICLE	IF	CITATIONS
145	Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 243-249.	1.6	11
146	Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy. <i>BJU International</i> , 2017, 120, 666-672.	2.5	7
147	Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment. <i>World Journal of Urology</i> , 2017, 35, 1833-1839.	2.2	17
148	Short- and Long-term Functional Outcomes and Quality of Life after Radical Prostatectomy: Patient-reported Outcomes from a Tertiary High-volume Center. <i>European Urology Focus</i> , 2017, 3, 615-620.	3.1	44
149	Reply to Jae Heon Kim, Bora Lee, and Benjamin I. Chung's Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. <i>Eur Urol</i> 2017;71:848-50. <i>European Urology</i> , 2017, 72, e176.	1.9	0
150	Reply to Paolo Capogrosso, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. <i>Eur Urol</i> 2017;71:848-50. Late Recovery of Erectile Function After Radical Prostatectomy: Should We Modify the Way of Assessment?. <i>European Urology</i> , 2017, 72, e179.	1.9	0
151	Biomarkers in prostate cancer - Current clinical utility and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 180-193.	4.4	135
152	High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. <i>European Urology</i> , 2017, 71, 848-850.	1.9	44
153	Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy. <i>BJU International</i> , 2017, 119, 717-723.	2.5	39
154	Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer. <i>World Journal of Urology</i> , 2017, 35, 1031-1036.	2.2	14
155	Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. <i>European Urology</i> , 2017, 71, 330-336.	1.9	57
156	Small renal masses in the elderly: Contemporary treatment approaches and comparative oncological outcomes of nonsurgical and surgical strategies. <i>Investigative and Clinical Urology</i> , 2016, 57, 231.	2.0	15
157	Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor. <i>European Urology Focus</i> , 2016, 2, 499-505.	3.1	55
158	The Role of Pelvic Lymph Node Dissection During Radical Prostatectomy in Patients With Gleason 6 Intermediate-risk Prostate Cancer. <i>Urology</i> , 2016, 93, 141-146.	1.0	7
159	Re: Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. <i>European Urology</i> , 2016, 70, 1079-1080.	1.9	0
160	Low Other Cause Mortality Rates Reflect Good Patient Selection in Patients with Prostate Cancer Treated with Radical Prostatectomy. <i>Journal of Urology</i> , 2016, 196, 82-88.	0.4	17
161	Impact of surgeon-defined capsular incision during radical prostatectomy on biochemical recurrence rates. <i>World Journal of Urology</i> , 2016, 34, 1547-1553.	2.2	2
162	Tumor Characteristics and Oncologic Outcome after Radical Prostatectomy in Men 75 Years Old or Older. <i>Journal of Urology</i> , 2016, 196, 89-94.	0.4	31

#	ARTICLE	IF	CITATIONS
163	Oncological, functional and perioperative outcomes in transplant patients after radical prostatectomy. <i>World Journal of Urology</i> , 2016, 34, 1101-1105.	2.2	10
164	Hormonal Treatment for Nonmetastatic Disease Recurrence After Curative Treatment of Prostate Cancer: Only for a Select Few. <i>European Urology</i> , 2016, 69, 821-822.	1.9	2
165	Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 119.e11-119.e18.	1.6	14
166	Identifying the Most Informative Prediction Tool for Cancer-specific Mortality After Radical Prostatectomy: Comparative Analysis of Three Commonly Used Preoperative Prediction Models. <i>European Urology</i> , 2016, 69, 1038-1043.	1.9	13
167	Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical Prostatectomy. <i>European Urology</i> , 2016, 69, 584-589.	1.9	119
168	Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteria. <i>BJU International</i> , 2016, 117, 55-61.	2.5	43
169	Impact of prostate volume on oncologic, perioperative, and functional outcomes after radical prostatectomy. <i>Prostate</i> , 2015, 75, 1436-1446.	2.3	17
170	Heterogeneity in D <sub>x</sub> <sup>3</sup> Amico classificationâ€based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 329.e13-329.e19.	1.6	37
171	Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical Prostatectomy. <i>Journal of Urology</i> , 2015, 193, 479-483.	0.4	46
172	External Validation of the CAPRA-S Score to Predict Biochemical Recurrence, Metastasis and Mortality after Radical Prostatectomy in a European Cohort. <i>Journal of Urology</i> , 2015, 193, 1970-1975.	0.4	50
173	Ultrasensitive Prostate Specific Antigen and its Role after Radical Prostatectomy: A Systematic Review. <i>Journal of Urology</i> , 2015, 193, 1525-1531.	0.4	22
174	Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer after Radical Prostatectomy. <i>Journal of Urology</i> , 2015, 193, 484-490.	0.4	66
175	The effect of age on functional outcomes after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 203.e11-203.e18.	1.6	66
176	The effect of BMI on clinicopathologic and functional outcomes after open radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 297-302.	1.6	25
177	EORTC Progression Score Identifies Patients at High Risk of Cancer-Specific Mortality After Radical Cystectomy for Secondary Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 278-286.	1.9	18
178	18F-Fluoroethylcholine PET/CT Identifies Lymph Node Metastasis in Patients with Prostate-Specific Antigen Failure After Radical Prostatectomy but Underestimates Its Extent. <i>European Urology</i> , 2013, 63, 792-796.	1.9	78
179	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. <i>World Journal of Urology</i> , 2012, 30, 807-814.	2.2	16
180	Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: Results from a single institution series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 508-514.	1.6	55

#	ARTICLE	IF	CITATIONS
181	Urine Markers for Detection and Surveillance of Nonâ€“Muscle-Invasive Bladder Cancer. European Urology, 2011, 60, 484-492.	1.9	176
182	Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome. European Urology, 2010, 58, 112-117.	1.9	51
183	pT3 Substaging is a Prognostic Indicator for Lymph Node Negative Urothelial Carcinoma of the Bladder. Journal of Urology, 2010, 184, 470-474.	0.4	29